A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus

Recruiting in Palo Alto (17 mi)

+53 other locations

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Eli Lilly and Company

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial is testing a new medication called LY3502970 to help people with type 2 diabetes control their blood sugar levels. It targets those who haven't had success with diet, exercise, or metformin. The study will last several months to see if LY3502970 is effective and safe.

Eligibility Criteria

Participant Groups

9Treatment groups

Experimental Treatment

Active Control

Placebo Group

Group I: 45 mg LY3502970 - 2Experimental Treatment1 Intervention

Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.

Group II: 45 mg LY3502970 - 1Experimental Treatment1 Intervention

Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.

Group III: 36 mg LY3502970 - 2Experimental Treatment1 Intervention

Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.

Group IV: 36 mg LY3502970 - 1Experimental Treatment1 Intervention

Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.

Group V: 3 milligrams (mg) LY3502970Experimental Treatment1 Intervention

Participants received maintenance dose of 3 mg with dose escalation starting from 2 mg LY3502970 administered orally once daily (QD).

Group VI: 24 mg LY3502970Experimental Treatment1 Intervention

Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally QD.

Group VII: 12 mg LY3502970Experimental Treatment1 Intervention

Participants received maintenance dose 12 mg with dose escalation starting from 2 mg, 6 mg and then 12 mg LY3502970 administered orally QD.

Group VIII: 1.5 mg DulaglutideActive Control1 Intervention

Participants received 1.5 mg Dulaglutide administered subcutaneously (SC) once weekly (QW).

Group IX: PlaceboPlacebo Group1 Intervention

Participants received matching placebo.